ONXX (ONYX PHARM INC)

Zecco.com
All Pro Portfolios with ONXX

People owning ONXX also tend to own:: AAADMCCRTCVXEWBCFMDMRO

All Do-It-Yourself Portfolios with ONXX
  • News For Selected Stock
  • Related stories on theStreet.com
  • videos related to etf's
  • No videos found
  •  
  • blogs related to etf's
  • No blogs found
  •  

Why I Love This Stock

By:sarah z

Date:09 12 08

From a recent Mad Money show: "I don't want you to sell this. Big pharma needs new drugs and Onyx has it. Onyx is a ticket to make money, not lose it."

Not yet rated
Rate now:

By:sarah z

Date:09 11 08

From a recent Mad Money show: "I don't want you to sell this. Big pharma needs new drugs and Onyx has it. Onyx is a ticket to make money, not lose it."

Not yet rated
Rate now:

By:barrons2

Date:08 16 08

Thapar and other analysts point to Onyx Pharmaceuticals (ONXX) as a potential target of Bayer. Onyx has a joint venture with the German pharmaceutical giant for Nexavar, which is used to treat kidney and liver cancers. "At some point, you could see Bayer wanting to control 100% of the assets," says Sustersic, who thinks that Bayer might pay as much as $65 per share. Nexavar is believed to have more upside, especially as it secures approval in other markets (it was recently given the green light by China as a liver-cancer treatment), and even more if it can be used for other cancers, including those of the breast, lungs and skin.

Not yet rated
Rate now:

By:barrons2

Date:08 06 08

News of the Bristol-Meyers (BMY) offer to buy out ImClone (IMCL) deal triggered a flurry of option activity in Amgen (AMGN),
Onyx Pharmaceuticals (ONXX), and Amylin (AMLN) said option strategist Frederic Ruffy.

Not yet rated
Rate now:

By:barrons2

Date:06 28 08

Buy - Price 34.75 on June 23
by Broadpoint Capital

CFO Greg Schafer resigned June 17 and will [depart] by Dec. 15...incrementally positive news for the stock (not a reflection on Schafer's ability), because we believe that it makes sense for new CEO Tony Coles to pick his own team....The most important piece of news, near term, [will be] announcement of Q208 Nexavar sales [for treating certain liver- and kidney-cancer patients] around July 30...We expect Nexavar sales will be significantly higher than most Street project[ions] and expect Onyx management will adjust its guidance for Nexavar sales for the year upward. Our 48 target appl[ies] a 30 times forward price/earnings multiple to our 2010 fully diluted EPS of $2.25. Market cap: $1.9 billion.

Not yet rated
Rate now:

By:stockerblog

Date:05 10 08

oral anticancer therapies used to prevent cancer cell proliferation and angiogenesis

Not yet rated
Rate now:

By:Pro

Date:11 30 -1

Biotech Investors Playing It Safe
TheStreet.com's biotech specialist, Adam Feuerstein, gives the highlights from the BioCEO Conference and explains why biotech investors may want to stick with ETFs for a while.

Click here to watch the video.

Not yet rated
Rate now:

By:Pro

Date:11 30 -1

Biotech Investors Playing It Safe
TheStreet.com's biotech specialist, Adam Feuerstein, gives the highlights from the BioCEO Conference and explains why biotech investors may want to stick with ETFs for a while.

Click here to watch the video.

Not yet rated
Rate now:

By:Pro

Date:11 30 -1

The Cancer Drug to Watch in 2008
Onyx Pharma's CEO gives his take on what's in store for 2008, and why a Nexavar lung cancer trial will be the big stock-moving event this year.

Click here to watch the video.

Not yet rated
Rate now:

By:pyromatic96

Date:01 04 08

POSSIBLE GROWTH

Not yet rated
Rate now:

Why I Hate This Stock

By:chrisblank

Date:03 03 08

I am taking a beating

Not yet rated
Rate now:

By:larry23

Date:02 22 08

dead wood

Not yet rated
Rate now:

By:tomvchris

Date:11 11 07

not enough room under favorites

Not yet rated
Rate now:

By:Primary278

Date:07 30 07

Lost too much money twice - never touch it again - just emoitional

Not yet rated
Rate now:

By:Nathan Weller

Date:02 13 07

Friedman Billings Ramsey Jim Reddoch downgraded Onyx to "Underperform" from "Market Perform," because its price had risen too high. The analyst also boosted his price target to $17 from $12.
In a research note, Reddoch warned that the liver cancer treatment market is still a small one with estimated U.S. sales of $187 million in 2010, up from the analyst's previous estimate of $72 million.
Nexavar also faces a threat from Sutent, a Pfizer Inc. drug that's currently approved for kidney cancer, Reddoch said. Nexavar received FDA-approval for kidney cancer in December 2005, and Sutent gained approval the next month. Sutent is currently in mid-stage clinical trials for liver cancer.

Not yet rated
Rate now:

By:Brian Walsh

Date:01 03 07

valuation

Not yet rated
Rate now:
Add Your Comments  
Stock ONXX
Allowed HTML tags: <a><b><i><img>
  Login to post your comments
Cramer's Take on Top-Searched St...

After a while, even investors get used to the bad news. Thursday started moderately low, a tempered response given all the recent bad news from retailers. But investo...

12.04.08 | 18:20 PM
Jim Cramer's Portfolios of the Week

Jim Cramer continues to find more reasons to be optimistic about the U.S. stock market. Recently, he has noticed that many new developments and changes are beginning to hap...

12.04.08 | 17:13 PM
Top Stocks With Insider Buying, ...

Part of the philosophy of Stockpickr is to follow in the footsteps of smart people. This could mean a few different things. First, it could mean piggybacking great inve...

12.04.08 | 10:36 AM
Latest News in Activist Investing

Since most hedge funds get paid based on their returns for the year, managers who want to get the most out of a stock investment often turn to shareholder activism as a way...

12.03.08 | 17:46 PM
more articles
General market Technical Analysi...
11.14.07 | 22:55 PM From author ZackAttack
cramer for sec chair
12.04.08 | 18:58 PM From author valuemac
Housing Market
12.04.08 | 17:39 PM From author MTnews
more forums
Q. Since we already know tomorrows ...
12.04.08 | 17:05 PM Asked by blitz373

A. No...its not priced into the market

IMO, A lot of the bad news is not
priced, but people like blitz373 keep
buying at these prices anyway. I want
sp500 topping at like 750. After we get
real, buyers can handle the ups and
downs.

today 's lists
TheStreet.com TV Videos - Nov. 24

These are some of the stocks mentioned today on TheStreet.com TV. Click the URL below each stock to watch the videos. more

Stocks Most Likely to Disappoint

This list consists of stocks that have had very nice up move over the last year and may be poised to disappoint going forward. The basis for the list is as follows: 52 w... more

Stocks With Unusual Option Activity

Unusually active options can often indicate that a major event in a stock is about to take place, or that unsophisticated investors (using options in lieu of leverage) are ... more